Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
Patricia WinokurJuleen GayedDavid Fitz-PatrickStephen J ThomasOyeniyi DiyaStephen LockhartXia XuYing ZhangVishva BangadHoward I SchwartzDouglas DenhamJose F CardonaLisa UsdanJohn GinisFederico J MensaJing ZouXuping XiePei-Yong ShiClaire LuSandra BuitragoIngrid L ScullyDavid CooperKenneth KouryKathrin U JansenÖzlem TüreciUğur ŞahinKena A SwansonWilliam C GruberNicholas Kitchinnull nullPublished in: The New England journal of medicine (2023)
The candidate monovalent or bivalent omicron BA.1-adapted vaccines had a safety profile similar to that of BNT162b2 (30 μg), induced substantial neutralizing responses against ancestral and omicron BA.1 strains, and, to a lesser extent, neutralized BA.4, BA.5, and BA.2.75 strains. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04955626.).